These data suggest that, in response to dabrafenib and dabrafenib+trametinib, BRAF-mut melanoma cells activate the axis SEMA6A/RhoA/YAP as a compensatory mechanism aimed to sustain actin cytoskeleton remodeling. This evidence concerns the gene SEMA6A and melanoma.